Prometheus Biosciences (RXDX) Surges 166% as Drug PRA023 Overshoots Drug’s Expectations

Prometheus Biosciences (RXDX) skyrocketed 166% on the news that their drug PRA023 exceeded expectations in patients with ulcerative colitis and Crohn’s disease.

“Net-net, the results exceed our expectations,” said RBC Capital Markets analyst Gregory Renza. They provide “key proof-of-concept in irritable bowel disease, early validation on the biomarker strategy and positive read-through to the (second ulcerative colitis data set) now set for the second quarter of 2023.”

In addition, SVB Securities analyst Thomas Smith noted that the drug showed a “”remarkably clean safety/tolerability profile across both studies.”

About Prometheus

Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. The company’s precision medicine platform, Prometheus360TM, combines proprietary machine learning-based analytical approaches with one of the world’s largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets.

About the Author

Prometheus Biosciences (RXDX) Surges 166% as Drug PRA023 Overshoots Drug’s Expectations

Investors Prism